Q-omics provides the consensus-scored LPIN3 profile across patient tissues and cancer cell-line models. LPIN3 expression is associated with patient survival in 28 of 34 cancer types, with the highest sampling consensus in OV. Among the 18 cancer types available for tumor–normal comparison, LPIN3 is differentially expressed in 16, with the highest sampling consensus in KIRC. Additionally, LPIN3 RNA expression shows 19,026 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight OV, KIRC, and UVM as cancer lineages where LPIN3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LPIN3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LPIN3 survival associations across molecular data types. LPIN3 RNA expression shows survival associations in the most cancer types (28), followed by mutation status (6) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LPIN3 RNA expression–survival associations across cancer types. High LPIN3 expression shows unfavorable associations in OV, KIRC, LGG, UVM, UCEC and LIHC. The OV Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify OV as the clearest survival context for LPIN3 RNA expression.
This table summarizes LPIN3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 16, while mass-spec protein shows differences in 3. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for LPIN3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LPIN3 shows lower tumor expression in THCA and higher tumor expression in KIRC, COAD, KIRP, LUSC and LIHC. The KIRC box plot shows higher LPIN3 RNA expression in tumor versus normal tissue (log2 FC = +1.092, t-test p < 0.001).
This table shows molecular features associated with LPIN3 in patient tissues and cancer cell lines. In patient samples, LPIN3 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, LPIN3 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LIVER, while CRISPR and shRNA rows add functional-dependency signals in LUNG_SCLC and UPPER_AERODIGESTIVE_TRACT.
